Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management
JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments
SE Combs, C Belka, M Niyazi, S Corradini… - Radiation …, 2020 - Springer
The COVID-19 pandemic is challenging modern radiation oncology. At University Hospitals,
we have a mandate to offer high-end treatments to all cancer patients. However, in times of …
we have a mandate to offer high-end treatments to all cancer patients. However, in times of …
Hypofractionated radiotherapy for prostate cancer
NS Hegemann, M Guckenberger, C Belka… - Radiation …, 2014 - Springer
In the last few years, hypofractionated external beam radiotherapy has gained increasing
popularity for prostate cancer treatment, since sufficient evidence exists that prostate cancer …
popularity for prostate cancer treatment, since sufficient evidence exists that prostate cancer …
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a …
C Carrie, A Hasbini, G de Laroche, P Richaud… - The Lancet …, 2016 - thelancet.com
Background How best to treat rising prostate-specific antigen (PSA) concentration after
radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need …
radical prostatectomy is an urgent clinical question. Salvage radiotherapy delays the need …
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013
A Heidenreich, PJ Bastian, J Bellmunt, M Bolla… - European urology, 2014 - Elsevier
Context The most recent summary of the European Association of Urology (EAU) guidelines
on prostate cancer (PCa) was published in 2011. Objective To present a summary of the …
on prostate cancer (PCa) was published in 2011. Objective To present a summary of the …
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
A Heidenreich, J Bellmunt, M Bolla, S Joniau, M Mason… - European urology, 2011 - Elsevier
OBJECTIVE: Our aim was to present a summary of the 2010 version of the European
Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of …
Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of …
Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally …
MD Mason, WR Parulekar, MR Sydes… - Journal of Clinical …, 2015 - ascopubs.org
Purpose We have previously reported that radiotherapy (RT) added to androgen-deprivation
therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we …
therapy (ADT) improves survival in men with locally advanced prostate cancer. Here, we …
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a …
K Fizazi, L Faivre, F Lesaunier, R Delva… - The Lancet …, 2015 - thelancet.com
Background Early risk-stratified chemotherapy is a standard treatment for breast, colorectal,
and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and …
and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and …
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial
ND James, MR Spears, NW Clarke… - JAMA …, 2016 - jamanetwork.com
Importance The natural history of patients with newly diagnosed high-risk nonmetastatic
(M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care …
(M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care …
Clinically localized prostate cancer: AUA/ASTRO guideline. Part III: principles of radiation and future directions
JA Eastham, GB Auffenberg, DA Barocas… - Journal of …, 2022 - journals.lww.com
Purpose: The summary presented herein represents Part III of the three-part series
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …
dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing …